DCAL Dishman Carbogen Amcis Q2 FY26 results (Jul–Sep 2025) and concall
Dishman Carbogen Amcis reported a strong Q2 and H1 FY26, driven by robust operating profit and cash generation. The company saw significant margin expansion, particularly in its CDMO segment due to late-phase molecule supplies. Strategic initiatives like the French subsidiary's GMP certification, expansion in the Chinese market, and integration efforts between Swiss and Indian operations are progressing well, contributing to a positive outlook for future growth and profitability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 35.5%, net profit down 200.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 93 | 97 | 106 | 63 | 60 −35% |
| EBITDA | 13 | 23 | 21 | 3 | 4 −69% |
| Net profit | 14 | -13 | -7 | 3 | -14 −200% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
